替妥木单抗减少甲状腺眼病眼外肌与眶脂肪体积
本研究基于OPTIC试验中6例活动性甲状腺眼病患者的眶部影像(CT或MRI),回顾性分析替妥木单抗治疗24周前后的三维体积变化,并与12例非甲状腺眼病患者对照。结果显示治疗后眼外肌总体积在所有12只眼眶中显著减少(p<0.02),眶脂肪体积在12只眼眶中的11只减少(p=0.04),基于MRI信号强度比的眼外肌炎症在8只眼眶中均减轻(p<0.01)。
要点
- 替妥木单抗治疗24周后所有12只眼眶眼外肌总体积显著减少(p<0.02)。
- 治疗后眼外肌体积与非甲状腺眼病对照组无统计学差异。
- 眶脂肪体积在12只眼眶中的11只减少(p=0.04),MRI信号强度比示炎症在8只眼眶中均减轻(p<0.01)。
核心结论
- 眶部影像显示替妥木单抗治疗后眼外肌体积和眶脂肪组织体积均减少。
研究设计与样本
- 回顾性研究,纳入OPTIC试验(NCT03298867)中6例接受24周替妥木单抗治疗并有治疗前后眶部影像的活动性甲状腺眼病患者。
- 另分析12例非甲状腺眼病患者(24只眼眶)作为对照。
- 使用经验证的图像处理软件进行眼外肌、眶脂肪和骨性眼眶的三维体积计算。
主要发现
- 每只眼眶眼外肌总体积在替妥木单抗治疗后均显著减少(6例患者,12/12只眼眶,p<0.02)。
- 治疗后眼外肌体积与非甲状腺眼病对照组无统计学差异。
- 眶脂肪总体积在12只研究眼眶中的11只减少(6例患者,p=0.04)。
- 基于MRI信号强度比的总体眼外肌炎症在8/8只眼眶中减轻(4例患者,p<0.01)。
临床怎么用
- 眶部影像三维体积分析可用于评估替妥木单抗治疗甲状腺眼病后眼外肌和眶脂肪的体积及炎症变化。
局限性
- 回顾性设计且样本量小(6例替妥木单抗治疗患者和12例对照)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Thyroid eye disease (TED) is a progressive, debilitating and potentially vision-threatening autoimmune disease. Teprotumumab, a novel human monoclonal antibody, has been shown to reverse the clinical manifestations of TED. Patients receiving teprotumumab have been shown in two multicenter, randomized placebo-controlled trials to have decreased proptosis, diplopia and inflammation after 24 weeks of treatment. This study aims to analyse volumetric and inflammatory changes on orbital imaging prior to and after teprotumumab treatment from one of these trials. DESIGN: Retrospective review. SUBJECTS: Six patients enrolled in the phase III teprotumumab clinical trial (OPTIC, NCT03298867) with active TED who received 24 weeks of teprotumumab and had pre- and post-treatment orbital imaging (CT or MRI). Additionally, 12 non-TED patients (24 orbits) were analysed as a comparative control group. METHODS: 3D volumetric calculations of the extraocular muscles (EOMs), orbital fat, and bony orbit were measured using previously validated image processing software. 3D volumetric results and changes in EOM inflammation were compared with clinical measurements of TED. RESULTS: Total EOM volume within each orbit was markedly reduced post-teprotumumab in all patients (n=six patients, 12/12 orbits, p<0.02). There was no statistical difference in post-treatment EOM volume when compared to non-TED controls. Total orbital fat volume was also reduced in 11 of 12 studied orbits (n=six patients, p=0.04). Overall EOM inflammation based on MRI signal intensity ratio was reduced in 8/8 orbits (n=four patients, p<0.01). CONCLUSION: Orbital imaging demonstrated decreased EOM volumes and orbital fat tissue volumes after teprotumumab treatment.
引用
- Jain AP, Gellada N, Ugradar S, et al. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2020. PMID: 33172865. doi:10.1136/bjophthalmol-2020-317806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。